0. DOCID:23876 SCORE: 0.00384243322074803
DOCNO: 7951271
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: methods
QUALIFIER: drug therapy
QUALIFIER: statistics & numerical data
AUTHOR: D Faries D
AFFILIATION: Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana 46285.
PUBTYPE: Journal Article
JOURNALTITLE: Journal of biopharmaceutical statistics.
COUNTRY: UNITED STATES
TITLE: Practical modifications of the continual reassessment method for phase I cancer clinical trials.
PUBDATE: 19940701
The continual reassessment method (1) (CRM) for phase I cancer trials provides improved estimation of the maximum tolerated dose (MTD), and fewer patients receive ineffective dose levels compared to the traditionally used design. However, the CRM has not gained acceptance in practice owing to concerns with administering dose levels that are too toxic. In this article, several conservative modifications of the CRM are introduced. The result is a procedure that improves estimation of the MTD and decreases the use of ineffective doses, without significantly increasing the use of toxic dose levels. The CRM with modification outperforms the traditional method in a simulation study.

1. DOCID:30435 SCORE: 0.00379282411847839
DOCNO: 12206638
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: radiotherapy
AUTHOR: R Subramaniam R
AUTHOR: S J Arnott SJ
AUTHOR: M D Leslie MD
AFFILIATION: St Thomas' Hospital, London, UK.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Clinical oncology (Royal College of Radiologists (Great Britain))
COUNTRY: England
TITLE: Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy.
PUBDATE: 20020801
Repeat radical irradiation of the pelvis is generally not undertaken because of concerns regarding normal tissue damage; in particular to small bowel, bladder and bone. Two patients with carcinoma of the anal canal are presented who had previously been treated by radical pelvic radiotherapy for gynaecological malignancy. Both were re-treated with radical radiotherapy to the pelvis with concomitant chemotherapy. A complete remission of anal cancer was achieved in both patients with minimal acute and late toxicities.

2. DOCID:2485 SCORE: 0.00366003329436751
DOCNO: 67887
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Carcinogens
DESCRIPTOR: Mutagens
QUALIFIER: adverse effects
QUALIFIER: drug effects
QUALIFIER: drug effects
AUTHOR: W F Benedict WF
AUTHOR: A Banerjee A
AUTHOR: A Gardner A
AUTHOR: P A Jones PA
PUBTYPE: Journal Article
JOURNALTITLE: Cancer research.
COUNTRY: UNITED STATES
TITLE: Induction of morphological transformation in mouse C3H/10T1/2 clone 8 cells and chromosomal damage in hamster A(T1)C1-3 cells by cancer chemotherapeutic agents.
PUBDATE: 19770701
Various cancer chemotherapeutic agents including alkylating agents, antimetabolites, and antibiotics or natural products were studied for their ability to produce morphological transformation in the C3H/10T1/2 clone 8 mouse cell line and chromosomal damage in the A(T1)C1-3 hamster cell line following a 24-hr exposure of each agent at different concentrations. Those drugs that were known to be carcinogenic in vivo also produced morphological transformation and chromosomal damage, whereas those agents that have not been shown to be carcinogenic in vivo produced neither transformation nor chromosomal lesions. The concentrations used for these studies were in general similar to those actually reached in the plasma of patients treated with these same drugs for malignant, as well as certain nonmalignant, conditions.

3. DOCID:2248 SCORE: 0.00325287793221342
DOCNO: 1192373
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: etiology
AUTHOR: W D DeWys WD
AUTHOR: K Walters K
PUBTYPE: Journal Article
JOURNALTITLE: Cancer.
COUNTRY: UNITED STATES
TITLE: Abnormalities of taste sensation in cancer patients.
PUBDATE: 19751101
In fifty patients with cancer, subjective and objective correlates of anorexia of malignancy were studied. Decreased taste was reported by 25 patients, and an aversion for meat was reported by 16 patients. The decreased taste symptom correlated with an elevated taste threshold for sweet (sucrose), and the symptom of meat aversion correlated with a lowered taste threshold for bitter (urea). The likelihood of having a taste abnormality increased with increasing extent of disease, but not with histologic type of neoplasm. Patients with an abnormality of taste had an increased incidence of weight loss compared with patients with normal taste, even though many in the latter group had other causes of weight loss. These observations suggest that an abnormality of taste may be one determinant of the anorexia of malignancy. Better understanding of the anorexia in the cancer patient may contribute to the care of the patient.

4. DOCID:16551 SCORE: 0.00323988422524013
DOCNO: 1958849
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
AUTHOR: J A Wils JA
AFFILIATION: Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Anti-cancer drugs.
COUNTRY: ENGLAND
TITLE: Chemotherapy in pancreatic cancer: a rational pursuit?
PUBDATE: 19910201
A review on the chemotherapy in advanced pancreatic cancer is presented. Pancreatic cancer is an extremely chemotherapy resistant tumor and results of cytostatic drug treatment so far are unsatisfactory. For patients with locally advanced disease the combination of chemo- and radiotherapy may palliate some patients. To date no standard treatment is available and patients should be entered in clinical protocols assessing new treatment options.

5. DOCID:26089 SCORE: 0.00309487437857393
DOCNO: 10687889
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug effects
QUALIFIER: drug therapy
QUALIFIER: metabolism
QUALIFIER: analogs & derivatives
AUTHOR: P S Sastry PS
PUBTYPE: Journal Article
JOURNALTITLE: Medical hypotheses.
COUNTRY: ENGLAND
TITLE: Prevention of progression in chronic myeloid leukemia by altering DNA methylation with a pyridoxine analogue.
PUBDATE: 19991201
Altered DNA methylation is one mechanism by which progression might occur in tumors. Progression in chronic myeloid leukemia (CML) was initially thought to be due to mutations. However, altered DNA methylation might be responsible for the same. An agent whose probable target is DNA methylation has been shown to improve hematopoiesis in CML. Pyridoxine is involved in methylation reactions. At present, the link between dietary factors like pyridoxine and cancer is somewhat tenuous. It is hypothesized that a suitable pyridoxine analogue might, by blocking DNA methylation, prevent progression in CML.

6. DOCID:1912 SCORE: 0.00307503910389699
DOCNO: 868056
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
AUTHOR: H L Duthie HL
PUBTYPE: Journal Article
JOURNALTITLE: World journal of surgery.
COUNTRY: MEXICO
TITLE: Surgery for gastric ulcer.
PUBDATE: 19770101
Despite the initial healing achieved by medical treatment with carbenoxolone, surgery is frequently needed in the management of gastric ulcer. We have studied 150 patients over the past 10 years in an attempt to define the place of conservative surgery compared with the standard partial gastrectomy of the Billroth I type. Functional results have not been significantly different and the individual surgeon's choice will depend on his philosophy with regard to the risk of cancer in the postoperative stomach, and his technical expertise with the newer kinds of vagotomy. To my mind it is perfectly justifiable to use highly selective vagotomy with excision of the ulcer to treat gastric ulcer alone, especially if the patient is one in whom postgastrectomy symptoms could be disabling. Further follow-up is needed to decide whether it should replace partial gastrectomy as the standard procedure.

7. DOCID:11576 SCORE: 0.003068318126984
DOCNO: 3912623
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Menopause
QUALIFIER: therapeutic use
QUALIFIER: therapy
QUALIFIER: therapeutic use
AUTHOR: A Wallgren A
AUTHOR: E Baral E
AUTHOR: U Glas U
AUTHOR: L Karnström L
AUTHOR: B Nordenskiöld B
AUTHOR: N O Theve NO
AUTHOR: C Silfverswärd C
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
PUBTYPE: Randomized Controlled Trial
JOURNALTITLE: Journal of steroid biochemistry.
COUNTRY: ENGLAND
TITLE: Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer.
PUBDATE: 19851201
Between November 1, 1976 and December 31, 1981, 826 post-menopausal females with operable breast cancer were included into a trial comparing tamoxifen 40 mg daily for 2 years with no endocrine treatment. Patients without axillary lymph node metastases and tumors less than 30 mm received no other treatment whilst those with more advanced disease were in addition superrandomised to receive postoperative irradiation or 12 courses of CMF. With a mean follow-up of 44 months tamoxifen significantly reduced the incidence of recurrence. There was no significant interaction between the effect of tamoxifen and any other treatment or prognostic subgroup.

8. DOCID:11522 SCORE: 0.00306831812674997
DOCNO: 2414044
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Antibodies, Monoclonal
QUALIFIER: blood
QUALIFIER: blood
QUALIFIER: enzymology
AUTHOR: D W Moss DW
AUTHOR: C H Self CH
AUTHOR: K B Whitaker KB
AUTHOR: E Bailyes E
AUTHOR: K Siddle K
AUTHOR: A Johannsson A
AUTHOR: C J Stanley CJ
AUTHOR: E H Cooper EH
PUBTYPE: Journal Article
JOURNALTITLE: Clinica chimica acta; international journal of clinical chemistry.
COUNTRY: NETHERLANDS
TITLE: An enzyme-amplified monoclonal immunoenzymometric assay for prostatic acid phosphatase.
PUBDATE: 19851001
An immunoassay for prostatic acid phosphatase is described in which a high degree of specificity for the prostatic isoenzyme, obtained by the use of monoclonal antibodies, is combined with great sensitivity, made possible by enzyme-amplified measurement of the combination of the isoenzyme with its antibody. The increase in sensitivity thus achieved is of the order of 170 times that of conventional methods of measurement. The advantages of the enzyme-amplified method have been shown to be particularly useful in detecting and monitoring small abnormalities of prostatic acid phosphatase levels in patients with prostatic cancer.

9. DOCID:3699 SCORE: 0.00299863777992834
DOCNO: 1234637
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: metabolism
QUALIFIER: enzymology
QUALIFIER: metabolism
QUALIFIER: enzymology
AUTHOR: W H Fishman WH
AUTHOR: N R Inglis NR
AUTHOR: J Vaitukaitis J
AUTHOR: L L Stolbach LL
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: National Cancer Institute monograph.
COUNTRY: UNITED STATES
TITLE: Regan isoenzyme and human chorionic gonadotropin in ovarian cancer.
PUBDATE: 19751001
Among 833 cancer patients whose sera were investigated for Regan isoenzyme and among 1,319 cancer patients from a different population whose sera were assayed for human chorionic gonadotropin (HCG), those patients with neoplasms of the testis or ovary showed the highest frequency of both placental proteins. Among another 22 patients with ovarian cancer, for whom both placental proteins were measured, 59% showed Regan isoenzyme and 68% showed HCG in ascitic fluids, whereas the figures were 65% and 30%, respectively, for sera. In 55% of both fluids and sera, there was a positive correlation of Regan isoenzyme with HCG (positive or negative). Almost invariably, the ascitic fluid was richer in Regan isoenzyme and HCG than the serum when both were collected on the same day. Progressively increasing levels of each placental protein generally correlated with the spread of the disease, though there were instances when only one was expressed. Evidence indicated the existence of two forms of alkaline phosphatase in ovarian cancer, Regan and non-Regan; the latter was assumed to be of fetal origin. Ultrastructural studies of one ovarian cancer revealed a morphologic entity, i.e., mitochondria enveloped by inverted tubules of endoplasmic reticulum.

10. DOCID:15747 SCORE: 0.00290717893744388
DOCNO: 3959337
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: K Namatame K
AUTHOR: M Ookubo M
AUTHOR: K Suzuki K
AUTHOR: H Sagawa H
AUTHOR: T Nagashima T
AUTHOR: Y Kataba Y
AUTHOR: U Maruyama U
AUTHOR: H Watanabe H
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Gan no rinsho. Japan journal of cancer clinics.
COUNTRY: JAPAN
TITLE: [A clinicopathological study of five cases of adenosquamous carcinoma of the stomach]
PUBDATE: 19860201
Five cases of adenosquamous carcinoma with resected stomach were subjected to this study, and the clinicopathological characteristics of this condition were described. The five patients represented 0.8% of 589 cases of resected stomach. There were two men and three women ranging in age from 40 to 70 (average, 62.8). Macroscopically, the adenosquamous carcinomas were all advanced gastric cancer situated in the lower body along the lesser curvature of the stomach, averaging 7.6 cm in size. The characteristic finding was the histologically differentiated type, invading to the serosa. Lymph node metastasis was most prominent.

11. DOCID:3500 SCORE: 0.00290484844220858
DOCNO: 1111936
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapy
AUTHOR: F Ghavimi F
AUTHOR: P R Exelby PR
AUTHOR: G J D'Angio GJ
AUTHOR: W Cham W
AUTHOR: P H Lieberman PH
AUTHOR: C Tan C
AUTHOR: V Miké V
AUTHOR: M L Murphy ML
PUBTYPE: Journal Article
JOURNALTITLE: Cancer.
COUNTRY: UNITED STATES
TITLE: Multidisciplinary treatment of embryonal rhabdomyosarcoma in children.
PUBDATE: 19750301
Twenty-nine children under 15 years of age with embryonal rhabdomyosarcoma were treated according to a multidisciplinary protocol (T-2). The protocol consisted of surgical removal of the tumor if possible, followed by chemotherapy, and also with radiation therapy in patients with gross or microscopic residual disease. Radiation therapy was given in the 4500-7000 rads range. The chemotherapy consisted of cycles of sequential administration of dactinomycin, Adriamycin, vincristine, and cyclophosphamide, with obligatory periods of rest. The drug therapy was continued for 2 years. Following surgery, clinicopathologic staging of the disease revealed 10 patients with no residual disease (I-A), 5 with microscopic residual disease (I-B), 5 with unresectable tumors (II), 6 with unresectable tumors plus regional lymph node involvement (III), and 3 with disseminated tumors (IV). Twenty-four (82%) of the patients (20 Stages I-II, 4 Stage III) are alive with no evidence of disease for 4 plus to 42 plus months. These results are superior to those achieved between 1960-1970 among 108 children treated at Memorial Sloan-Kettering Cancer Center.

12. DOCID:7261 SCORE: 0.00286561521290796
DOCNO: 7376260
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Antibody Specificity
QUALIFIER: immunology
QUALIFIER: immunology
AUTHOR: L Bellelli L
AUTHOR: M L Sezzi ML
PUBTYPE: Journal Article
JOURNALTITLE: Tumori.
COUNTRY: ITALY
TITLE: Non-specifically bound immunoglobulins on mouse placental cells.
PUBDATE: 19800201
There seem to be some similarities between mechanisms employed by embryos and cancer cells from the maternal or tumor bearer's immune system. In the present study, we investigated the presence of hemagglutinins on placental cells and their relationship to circulating antibodies in mice immunized against sheep erythrocytes before mating. The results obtained demonstrated that placental cells may fix large quantities of maternal immunoglobulins. The hemagglutinins are probably fixed on placental cells by the Fc, since the combining sites of the antibody were free and able to react with the antigen in the "rosette" test. It was also demonstrated that placental tissue may fix up to 1/4 of the maternal circulating antibodies, while only 1/200 of them were transmitted to the fetuses. Some theoretical implications of the presence in the placenta of antibodies not directed against feto-placental antigens are also discussed.

13. DOCID:5588 SCORE: 0.00282954810215043
DOCNO: 392384
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: epidemiology
QUALIFIER: epidemiology
AUTHOR: F Nöthiger F
PUBTYPE: Journal Article
JOURNALTITLE: Onkologie.
COUNTRY: SWITZERLAND
TITLE: [Colorectal cancer]
PUBDATE: 19790801
Incidence of colorectal cancer is increasing during the last years. 5% of the population get affected. From these a group of patients with a higher carcinoma risk must be separated: that with adenomas, familial polyposis and ulcerative colitis. Nourishment seems to be one of the main factors for the development of cancer. Although all important principles of radical surgery are realized, this 5-year survival rate for colorectal cancer is less than 40%. Prophylaxis, early diagnosis and the effect of irradiation and drug therapy must improve the relatively poor prognosis of colorectal cancer, which has reached in Germany the highest mortality and even -- with the exception of skin cancer -- the highest morbidity of all malignant neoplastic diseases.

14. DOCID:14176 SCORE: 0.0028239769442438
DOCNO: 12341459
OWNER: PIP
STATUS: MEDLINE
DESCRIPTOR: Cause of Death
DESCRIPTOR: Cerebrovascular Circulation
DESCRIPTOR: Digestive System
DESCRIPTOR: Geography
DESCRIPTOR: Life Expectancy
DESCRIPTOR: Mortality
DESCRIPTOR: Neoplasms
DESCRIPTOR: Suicide
AUTHOR: Y Mao Y
AUTHOR: L Fortier L
AUTHOR: D Wigle D
PUBTYPE: Journal Article
JOURNALTITLE: Cahiers québécois de démographie / Association des démographes du Québec.
COUNTRY: CANADA
TITLE: [Evolution of Quebec's mortality rates, by cause of death]
PUBDATE: 19870401
"The evolution of mortality in Quebec over the past three decades is reviewed. Life expectancies and potential years of life lost from birth to age 75 are calculated. Also, interprovincial comparisons of mortality are included. Quebec's mortality experience, in comparison to the other provinces, is poor. Causes of death that are of particular concern are suicide and lung cancer. Mortality rates for cerebrovascular diseases, stomach cancer and kidney diseases have markedly declined, for males as well as females." (SUMMARY IN ENG AND SPA)